Status:

COMPLETED

Diabetes Education With Real-time Continuous Glucose Monitoring

Lead Sponsor:

University of Washington

Collaborating Sponsors:

American Diabetes Association

Washington State University

Conditions:

Diabetes Type 2

Eligibility:

All Genders

18-60 years

Phase:

NA

Brief Summary

Determine the impact of the Compañeros en Salud (Partners in Health) curriculum in conjunction with RT-CGM on glycemic control in Latinx patients with T2D. Participants will be randomized to receive t...

Detailed Description

The prevalence of type 2 diabetes is increasing especially in the Latinx community and in family members of those already living with diabetes. Diabetes education is a cornerstone of treatment but is ...

Eligibility Criteria

Inclusion

  • Inclusion Criteria:
  • Participants adults 18-60 years old
  • Self-identify as Latinx
  • Have had a clinical diagnosis of T2D within the last 15 years with or without medication use
  • Have an A1C ≥8.0% at screening
  • Own or have routine access to a personal device that allows attending educational sessions virtually
  • Be physically and cognitively able to use the home CGM monitoring device
  • Be willing and able to follow all other study procedures
  • Exclusion Criteria
  • Exclusion Criteria.
  • Duration of diabetes \>15 years
  • Type 1 diabetes or latent autoimmune diabetes
  • Current use of prandial insulin
  • Any condition that prevents walking at least 1 city block
  • History of serious mental illness other than adequately treated depression
  • History of bariatric surgery or current participation in a weight management program
  • Current diagnosis of cancer or other serious or systemic medical condition
  • Significant active cardio- or cerebrovascular disease after review by PI
  • Pregnancy
  • know history x of of hypoglycemia unawareness
  • Unable to read, understand, and sign the Informed Consent Form (ICF) and if applicable, an Authorization to Use and Disclose Protected Health Information form (consistent with Health Insurance Portability and Accountability Act of 1996 \[HIPAA\] legislation), communicate with the investigator, and understand and comply with protocol requirements

Exclusion

    Key Trial Info

    Start Date :

    November 11 2022

    Trial Type :

    INTERVENTIONAL

    Allocation :

    ACTUAL

    End Date :

    November 30 2024

    Estimated Enrollment :

    120 Patients enrolled

    Trial Details

    Trial ID

    NCT05394844

    Start Date

    November 11 2022

    End Date

    November 30 2024

    Last Update

    December 1 2025

    Active Locations (2)

    Enter a location and click search to find clinical trials sorted by distance.

    Page 1 of 1 (2 locations)

    1

    University of Washington Diabetes Institute

    Seattle, Washington, United States, 98109

    2

    University of Washington

    Seattle, Washington, United States, 98109